Structure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GPCR · as of Sep 30, 2025
Ownership Breakdown
175
Institutional Holders
▼ 12 vs Q2
$1.58B
Total Inst. Value
▲ $449.62M vs Q2
57.57M
Shares Outstanding
freeFloat 95.06%
56.66M
13F Shares Held
▲ 2.01M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GPCR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 5.69M | 9.73% | 9.73% | $159.30B | Nov 14, 2025 | ▼ 1.19M |
FMR LLC pharmaceutical preparations | 5.25M | 8.98% | 8.98% | $147.01B | Nov 13, 2025 | ▲ 335.4K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 5.16M | 8.81% | 8.81% | $144.36B | Nov 14, 2025 | NEW |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 4.45M | 7.61% | 7.61% | $124.60B | Nov 14, 2025 | ▼ 124.2K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 4.22M | 7.21% | 7.21% | $118.04B | Nov 14, 2025 | ▼ 918.1K |
BVF INC/IL pharmaceutical preparations | 3.20M | 5.48% | 5.48% | $89.71B | Nov 14, 2025 | ▲ 1.43M |
MORGAN STANLEY pharmaceutical preparations | 577.7K | 3.01% | 3.01% | $16.18B | May 27, 2026 | ▼ 339.6K |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 1.56M | 2.66% | 2.66% | $43.57B | Nov 14, 2025 | ▼ 952.7K |
CASDIN CAPITAL, LLC pharmaceutical preparations | 1.55M | 2.66% | 2.66% | $43.54B | Nov 14, 2025 | ▲ 330.0K |
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 1.52M | 2.59% | 2.59% | $42.49B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+5.00M shares5
New Positions
first time holders16
Decreased
−5.43M shares0
Sold Out
fully exitedNet shares change (top 50)
431.8K
+5.00M / −5.43M
Net new holders
+13
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GPCR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lang Matthew COO & GC | Apr 15, 2026 | Award | 223,776 | $18.08 | $4.05M | 223.8K | Form 4 ↗ |
Lang Matthew COO & GC | Apr 15, 2026 | Award | 184,614 | — | — | 184.6K | Form 4 ↗ |
FMR LLC See Remark 1 | Apr 14, 2026 | Sale | 16,085 | — | — | 32.2K | Form 4 ↗ |
FMR LLC See Remark 1 | Apr 14, 2026 | Sale | 1,367 | — | — | 2.7K | Form 4 ↗ |
Hall Ashley Chief Development Officer | Mar 19, 2026 | Award | 47,706 | — | — | 155.2K | Form 4 ↗ |
Hall Ashley Chief Development Officer | Mar 19, 2026 | Award | 59,073 | $16.82 | $993.6K | 59.1K | Form 4 ↗ |
Coll Crespo Blas CHIEF MEDICAL OFFICER | Mar 19, 2026 | Award | 75,897 | — | — | 280.9K | Form 4 ↗ |
Coll Crespo Blas CHIEF MEDICAL OFFICER | Mar 19, 2026 | Award | 93,984 | $16.82 | $1.58M | 94.0K | Form 4 ↗ |
Ma Yingli CHIEF TECHNOLOGY OFFICER | Mar 19, 2026 | Award | 32,526 | — | — | 139.9K | Form 4 ↗ |
Ma Yingli CHIEF TECHNOLOGY OFFICER | Mar 19, 2026 | Award | 40,278 | $16.82 | $677.5K | 40.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Structure Therapeutics Inc. (GPCR) is primarily owned by institutional investors, who hold approximately 98.4% of total shares outstanding. Company insiders own approximately 4.94%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Structure Therapeutics Inc. is WELLINGTON MANAGEMENT GROUP LLP, holding approximately 5.69 million shares — equal to 9.73% of outstanding shares — as of September 30, 2025.
A total of 175 institutional investors currently hold GPCR stock, with a combined institutional value of approximately $1.58 billion as of the most recent 13F filing period.
Frequently asked questions
GPCR ownershipStructure Therapeutics Inc. (GPCR) is primarily owned by institutional investors, who hold approximately 98.4% of shares. The largest shareholder is WELLINGTON MANAGEMENT GROUP LLP with a 9.73% stake. Company insiders hold 4.94%. Data sourced from SEC Form 13F as of September 30, 2025.